Table 2 Clinical characteristics of patients who received IORT.*

Type of breast surgery—no. (%)

 Quadrantectomy

249 (98.8)

 Quadrantectomy + mastectomy

3 (1.2)

Type of axillary management—no. (%)

 SLNB

252 (100)

Pathology subtype—no. (%)

 Invasive ductal carcinoma

227 (90.1)

 Invasive lobular carcinoma

6 (2.4)

 Invasive tubular carcinoma

5 (2)

 Mucinous

3 (1.2)

 Papillary

3 (1.2)

 Other

8 (3.2)

Tumor size—cm

1.56 ± 0.55

Tumor size—cm

 < 2

204 (87.2)

 2–2.5

28 (12)

 2.5–3

2 (0.9)

Tumor grade—no. (%)

 1

99 (44.6)

 2

92 (41.4)

 3

31 (14)

Grade of nucleus—no. (%)

 1

65 (43.9)

 2

51 (34.5)

 3

32 (21.7)

In-situ component—no. (%)

 Yes

157 (71.7)

 No

60 (27.4)

 Unknown

2 (0.9)

Tumor necrosis—no. (%)

 Yes

76 (38.6)

 No

120 (60.9)

 Unknown

1 (0.5)

Invasion—no. (%)

 Perineural

19 (8.6)

 Lymphatic-vascular

32 (14.5)

 All

10 (5)

 None

159 (71.9)

Lymph node involvement

 No

231 (91.6)

 Micrometastasis

21 (8.4)

Marginal involvement

 Negative

252 (100)

Esterogon receptor—no. (%)

 Positive

240 (100)

 Negative

0

Progesterone receptor—no. (%)

 Positive

225 (93.4)

 Negative

16 (6.6)

HER2 overexpression—no. (%)

 Positive

31 (14.6)

 Negative

182 (85.4)

Chemotherapy before surgery—no. (%)

 Yes

0

 No

252 (100)

Chemotherapy after surgery—no. (%)

 Yes

205 (83.7)

 No

40 (16.3)

IORT type—no. (%)

 Radical

252 (100)

Hormone therapy—no. (%)

 Yes

236 (98.3)

 No

4 (1.7)

Type of hormone therapy—no. (%)

 Tamoxifen

57 (24.2)

 Laterazole

154 (65.3)

 Tamoxifen + laterazole

22 (9.3)

 Aromasins

3 (1.3)

Recurrence—no. (%)

 Yes

8 (3.1)

 Local

4 (1.5)

 Regional

2 (0.8)

 Metastatic

2 (0.8)

 No

246 (96.9)

Mortality—no. (%)

 Yes

1 (0.3)

 No

251 (99.7)

Follow-up duration—months

 Mean

36.3 ± 18.7

 Median (IQR)

34.1 (23.1, 51.2)